Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma


Autoria(s): O'Byrne, Kenneth J.; Edwards, John G.; Waller, David A.
Data(s)

2004

Resumo

In the UK mortality from malignant mesothelioma (MM) is likely to more than double over the next 20 years and despite advances in surgery, chemotherapy and radiation treatment the overall prognosis for patients remains poor. A number of scoring systems based on assessment of clinicopathological features of patients with the disease have been developed but the search continues for further prognostic indicators. Angiogenesis, tumour necrosis (TN), epidermal growth factor receptor (EGFR) expression, cyclooxygenase-2 (COX-2) and matrix metalloproteinases (MMPs) have been linked with poor prognosis in some types of solid tumour and their relevance as prognostic factors in malignant mesothelioma is examined in this paper. © 2004 Elsevier Ireland Ltd. All rights reserved.

Identificador

http://eprints.qut.edu.au/65283/

Publicador

Elsevier Ireland Ltd

Relação

DOI:10.1016/j.lungcan.2004.04.025

O'Byrne, Kenneth J., Edwards, John G., & Waller, David A. (2004) Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer, 45(SUPPL.), S45-S48.

Direitos

Copyright 2004 Elsevier Ireland Ltd

Fonte

School of Biomedical Sciences; Faculty of Health; Institute of Health and Biomedical Innovation

Palavras-Chave #Angiogenesis #Cyclooxygenase (COX)-2 #Epidermal growth factor receptor expression #Matrix metalloproteinases #Prognostic factor #Tumour necrosis #celecoxib #cyclooxygenase 2 #epidermal growth factor receptor #matrix metalloproteinase #rofecoxib #tumor necrosis factor receptor #cancer chemotherapy #cancer mortality #cancer radiotherapy #cancer surgery #clinical trial #conference paper #human #malignant mesothelioma #priority journal #prognosis #Humans #Isoenzymes #Membrane Proteins #Mesothelioma #Neovascularization #Pathologic #Pleural Neoplasms #Prostaglandin-Endoperoxide Synthases #Receptor #Epidermal Growth Factor #Tumor Markers #Biological
Tipo

Journal Article